Meet Emerald Clinical’s Renal Experts —
8th Annual CKD Summit
Boston, March 16-18, 2026
Elevate your renal development strategy with a partner committed to innovation, quality, and patient impact.
Book a Meeting with Us
Meet Claudio Hegenberger, our Vice President, Scientific and Medical Affairs, Molly Bur Kitten, Senior Project Director, Scientific and Medical Affairs, and our Business Development Directors to understand how our world-renowned focus on renal research can help you navigate complexities for your trials.
Is your clinical strategy ready for the next generation of renal drug development?
We are proud to have served 15 of the top 20 pharmaceutical firms and 160+ biotechs, and we can help you.
| Expertise Across Renal Indications | End-to-End Renal Solutions |
|---|---|
| • Chronic Kidney Disease (CKD) • IgA Nephropathy (IgAN) • Focal Segmental Glomerulosclerosis (FSGS) • Acute Kidney Injury • Other rare and complex renal diseases | • Study Design & Start-Up – Protocol customization for clinical and regulatory success. • Patient Recruitment & Retention – Leveraging global networks for efficient enrollment. • Data Management & Biostatistics – Rigorous analytics driving scientific precision. • Safety & Pharmacovigilance – Proactive risk management and monitoring. |
Advancing Renal Drug Development Through Strategic Design
Renal drug development is entering a period of rapid scientific and clinical evolution, with emerging biomarkers, novel mechanisms, and increasingly competitive pipelines. To support this complexity, Emerald Clinical established the Renal Clinical Development Advisory Board to provide integrated, disease-specific strategic guidance across the development lifecycle.
Combining experienced drug developers with internationally recognized nephrologists, the advisory board supports evidence-based trial design, endpoint selection, and regulatory-ready strategies—helping sponsors de-risk programs and optimize clinical relevance from early development through pivotal studies.
Learn more about our Renal Advisory Board.
| “What we have is a global network of nephrologists who have delivered clinical trials and want to deliver more—and they know how to do it. Seeing these studies published in high-profile publications and new drugs getting approved for our patients justifies all the time and effort spent in delivering these clinical trials, and really changes clinical practice for the better.” Professor Jonathan Barratt, PhD, FRCP |
How we have helped our clients
Claudio Hegenberger MD, MBA, MSc
Molly Bur Kitten
Gail Frey
